On the public citation graph

Comprehensive analysis of cancers of unknown primary for the biomarkers of response to immune checkpoint blockade therapy

0 signed · 161 inferred · view as graph

Inferred edges come from two machine sources: sweeps of open repository metadata (mostly SSRN and Zenodo), and a bulk OpenAlex citation snapshot. Every row below is labelled with the one it came from. Neither is a complete citation index — absence here is not evidence of absence.

Is this your work? Sign in with ORCID and put your name on the claims that are yours.
Claim with ORCID
Reference health. See whether every reference in this work resolves to a known work and none has been retracted — and get a dated CiteStamped badge you can embed.
See reference health

What this work says

Outgoing claims: the papers this work cites, builds on, or argues with.

inferredcites →https://doi.org/10.1001/jamaoncol.2014.216openalex-snapshot
Comprehensive Genomic Profiling of Carcinoma of Unknown Primary Site
inferredcites →https://doi.org/10.1002/path.4251openalex-snapshot
Massively‐parallel sequencing assists the diagnosis and guided treatment of cancers of unknown primary
inferredcites →https://doi.org/10.1007/s10689-016-9884-6openalex-snapshot
High microsatellite instability (MSI-H) colorectal carcinoma: a brief review of predictive biomarkers in the era of personalized medicine
inferredcites →https://doi.org/10.1016/j.cell.2011.02.013openalex-snapshot
Hallmarks of Cancer: The Next Generation
inferredcites →https://doi.org/10.1016/j.cell.2014.06.049openalex-snapshot
Multiplatform Analysis of 12 Cancer Types Reveals Molecular Classification within and across Tissues of Origin
inferredcites →https://doi.org/10.1016/j.jtho.2016.11.238openalex-snapshot
OA03.01 First-Line Nivolumab Monotherapy and Nivolumab plus Ipilimumab in Patients with Advanced NSCLC: Long-Term Outcomes from CheckMate 012
inferredcites →https://doi.org/10.1016/s0140-6736(15)01281-7openalex-snapshot
Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial
inferredcites →https://doi.org/10.1016/s0140-6736(16)00561-4openalex-snapshot
Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial
inferredcites →https://doi.org/10.1016/s0140-6736(16)32517-xopenalex-snapshot
Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial
inferredcites →https://doi.org/10.1016/s1470-2045(16)30406-5openalex-snapshot
Predictive biomarkers for checkpoint inhibitor-based immunotherapy
inferredcites →https://doi.org/10.1016/s1470-2045(16)30496-xopenalex-snapshot
Nivolumab monotherapy in recurrent metastatic urothelial carcinoma (CheckMate 032): a multicentre, open-label, two-stage, multi-arm, phase 1/2 trial
inferredcites →https://doi.org/10.1016/s1470-2045(17)30065-7openalex-snapshot
Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial
inferredcites →https://doi.org/10.1038/nature12634openalex-snapshot
Mutational landscape and significance across 12 major cancer types
inferredcites →https://doi.org/10.1038/nature13904openalex-snapshot
MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer
inferredcites →https://doi.org/10.1056/nejmc1312697openalex-snapshot
RAS Mutations in Colorectal Cancer
inferredcites →https://doi.org/10.1056/nejmoa1006448openalex-snapshot
Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer
inferredcites →https://doi.org/10.1056/nejmoa1103782openalex-snapshot
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
inferredcites →https://doi.org/10.1056/nejmoa1406498openalex-snapshot
Genetic Basis for Clinical Response to CTLA-4 Blockade in Melanoma
inferredcites →https://doi.org/10.1056/nejmoa1412082openalex-snapshot
Nivolumab in Previously Untreated Melanoma without BRAF Mutation
inferredcites →https://doi.org/10.1056/nejmoa1500596openalex-snapshot
PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
inferredcites →https://doi.org/10.1056/nejmoa1507643openalex-snapshot
Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer
inferredcites →https://doi.org/10.1056/nejmoa1510665openalex-snapshot
Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma
inferredcites →https://doi.org/10.1056/nejmoa1606774openalex-snapshot
Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer
inferredcites →https://doi.org/10.1056/nejmoa1613683openalex-snapshot
Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma
inferredcites →https://doi.org/10.1093/annonc/mdv305openalex-snapshot
Cancers of unknown primary site: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
inferredcites →https://doi.org/10.1093/annonc/mdx545openalex-snapshot
Clinical and molecular characterization of patients with cancer of unknown primary in the modern era
inferredcites →https://doi.org/10.1101/mcs.a001180openalex-snapshot
Integration of genomics and histology revises diagnosis and enables effective therapy of refractory cancer of unknown primary with PDL1 amplification
inferredcites →https://doi.org/10.1111/eci.12062openalex-snapshot
Exploring the biology of cancer of unknown primary: breakthroughs and drawbacks
inferredcites →https://doi.org/10.1126/science.aaa4971openalex-snapshot
Neoantigens in cancer immunotherapy
inferredcites →https://doi.org/10.1126/science.aan6733openalex-snapshot
Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade
inferredcites →https://doi.org/10.1136/jclinpath-2016-203874openalex-snapshot
Comprehensive profiling of metaplastic breast carcinomas reveals frequent overexpression of programmed death-ligand 1
inferredcites →https://doi.org/10.1158/0008-5472.can-17-0628openalex-snapshot
Utility of Genomic Analysis In Circulating Tumor DNA from Patients with Carcinoma of Unknown Primary
inferredcites →https://doi.org/10.1158/1078-0432.ccr-12-3030openalex-snapshot
New Strategies for Carcinoma of Unknown Primary: The Role of Tissue-of-Origin Molecular Profiling
inferredcites →https://doi.org/10.1158/1078-0432.ccr-13-3271openalex-snapshot
Association of PD-1, PD-1 Ligands, and Other Features of the Tumor Immune Microenvironment with Response to Anti–PD-1 Therapy
inferredcites →https://doi.org/10.1158/1078-0432.ccr-16-1741openalex-snapshot
Hyperprogressive Disease Is a New Pattern of Progression in Cancer Patients Treated by Anti-PD-1/PD-L1
inferredcites →https://doi.org/10.1158/1078-0432.ccr-16-3133openalex-snapshot
Hyperprogressors after Immunotherapy: Analysis of Genomic Alterations Associated with Accelerated Growth Rate
inferredcites →https://doi.org/10.1158/2159-8290.cd-16-1223openalex-snapshot
Primary Resistance to PD-1 Blockade Mediated by JAK1/2 Mutations
inferredcites →https://doi.org/10.1200/edbook_am.2013.33.175openalex-snapshot
Cancer of Unknown Primary Site: Improved Patient Management with Molecular and Immunohistochemical Diagnosis
inferredcites →https://doi.org/10.1200/jco.2012.44.3937openalex-snapshot
Molecular Profiling for Druggable Genetic Abnormalities in Carcinoma of Unknown Primary
inferredcites →https://doi.org/10.1200/jco.2016.67.9761openalex-snapshot
Safety and Efficacy of Durvalumab (MEDI4736), an Anti–Programmed Cell Death Ligand-1 Immune Checkpoint Inhibitor, in Patients With Advanced Urothelial Bladder Cancer
inferredcites →https://doi.org/10.1200/jco.2016.72.1316openalex-snapshot
Phase II Study of the Efficacy and Safety of Pembrolizumab for Relapsed/Refractory Classic Hodgkin Lymphoma
inferredcites →https://doi.org/10.1200/jco.2017.35.15_suppl.4003openalex-snapshot
KEYNOTE-059 cohort 1: Efficacy and safety of pembrolizumab (pembro) monotherapy in patients with previously treated advanced gastric cancer.
inferredcites →https://doi.org/10.1371/journal.pone.0130142openalex-snapshot
Differential Activity of Nivolumab, Pembrolizumab and MPDL3280A according to the Tumor Expression of Programmed Death-Ligand-1 (PD-L1): Sensitivity Analysis of Trials in Melanoma, Lung and Genitourinary Cancers
inferredcites →https://doi.org/10.18632/oncotarget.21169openalex-snapshot
Comparative molecular analyses of left-sided colon, right-sided colon, and rectal cancers
inferredcites →https://doi.org/10.18632/oncotarget.2574openalex-snapshot
Comprehensive tumor profiling identifies numerous biomarkers of drug response in cancers of unknown primary site: Analysis of 1806 cases
inferredcites →https://doi.org/10.6004/jnccn.2014.0093openalex-snapshot
Occult Primary, Version 3.2014

What points at this work

Incoming claims: where this work appears in other papers’ reference lists and arguments.

inferred← citeshttps://doi.org/10.2139/ssrn.4857103openalex-extracted
A Phase II Study of Durvalumab and Tremelimumab in Patients with Advanced Rare Cancer
inferred← citeshttps://doi.org/10.1002/1878-0261.13664openalex-snapshot
Exploring the molecular landscape of cancer of unknown primary: A comparative analysis with other metastatic cancers
inferred← citeshttps://doi.org/10.1002/9781119000822.hfcm124.pub2openalex-snapshot
Neoplasms of Unknown Primary Site
inferred← citeshttps://doi.org/10.1002/cam4.1689openalex-snapshot
Cancer of unknown primary—Epidemiological trends and relevance of comprehensive genomic profiling
inferred← citeshttps://doi.org/10.1002/cam4.2602openalex-snapshot
Novel therapeutic targets in salivary duct carcinoma uncovered by comprehensive molecular profiling
inferred← citeshttps://doi.org/10.1002/cam4.2820openalex-snapshot
Comparison of the biomarkers for targeted therapies in primary extra‐mammary and mammary Paget's disease
inferred← citeshttps://doi.org/10.1002/cam4.5349openalex-snapshot
Clinical decisions by the molecular tumor board on comprehensive genomic profiling tests in Japan: A retrospective observational study
inferred← citeshttps://doi.org/10.1002/cnr2.70338openalex-snapshot
Successful Identification and Treatment of Cancer of Unknown Primary Originating From Gastric Cancer Using Comprehensive Genomic Profiling and Immune Checkpoint Inhibitor Therapy: A Case Report
inferred← citeshttps://doi.org/10.1002/gcc.23047openalex-snapshot
Prognostic impact of copy number alterations and tumor mutational burden in carcinoma of unknown primary
inferred← citeshttps://doi.org/10.1002/ijc.32316openalex-snapshot
Comparative genetic profiling aids diagnosis and clinical decision making in challenging cases of CUP syndrome
inferred← citeshttps://doi.org/10.1002/ijc.32882openalex-snapshot
Integrated Clinico-Molecular Characterization Identifies RAS Activation and CDKN2A Deletion As Independent Adverse Prognostic Factors in Cancer of Unknown Primary
inferred← citeshttps://doi.org/10.1002/mco2.70124openalex-snapshot
PD‐1/PD‐L1 Inhibitors Plus Chemotherapy Versus Chemotherapy Alone as First‐Line Therapy for Patients With Unfavorable Cancer of Unknown Primary: A Multicenter, Retrospective Cohort Study
inferred← citeshttps://doi.org/10.1002/mco2.70161openalex-snapshot
Advancements in Diagnostics and Therapeutics for Cancer of Unknown Primary in the Era of Precision Medicine
inferred← citeshttps://doi.org/10.1007/978-3-030-16391-4_4openalex-snapshot
Immunohistochemistry-Enabled Precision Medicine
inferred← citeshttps://doi.org/10.1007/978-3-030-84432-5_15openalex-snapshot
Treatment Approach to Carcinomas of Unknown Primary
inferred← citeshttps://doi.org/10.1007/978-3-662-46764-0_245-1openalex-snapshot
CUP-Syndrom – Tumorerkrankung mit unbekanntem Primärtumor
inferred← citeshttps://doi.org/10.1007/s00405-022-07775-zopenalex-snapshot
Comparison of PD-L1 expression in squamous cell cancer of unknown primary and oropharyngeal squamous cell carcinoma
inferred← citeshttps://doi.org/10.1007/s00432-025-06261-3openalex-snapshot
Clinical outcome and genomic biomarkers of immune checkpoint inhibitor-based therapies for cancer of unknown primary: a multicenter, real-world study
inferred← citeshttps://doi.org/10.1007/s00761-023-01442-6openalex-snapshot
„Cancer of unknown primary“ – histologische und molekularpathologische Grundlagen in der Diagnostik
inferred← citeshttps://doi.org/10.1007/s10147-024-02494-3openalex-snapshot
PD-L1 expression and microsatellite instability (MSI) in cancer of unknown primary site
inferred← citeshttps://doi.org/10.1007/s10555-023-10101-6openalex-snapshot
Carcinoma of unknown primary (CUP): an update for histopathologists
inferred← citeshttps://doi.org/10.1007/s12094-022-02806-xopenalex-snapshot
SEOM—GECOD clinical guideline for unknown primary cancer (2021)
inferred← citeshttps://doi.org/10.1007/s12094-026-04241-8openalex-snapshot
SEOM-GECOD clinical guideline for cancer of unknown primary (update 2025)
inferred← citeshttps://doi.org/10.1007/s12254-023-00935-9openalex-snapshot
Cancer of unknown primary—state of the art
inferred← citeshttps://doi.org/10.1007/s12254-025-01099-4openalex-snapshot
Bridging the gap: targeted treatment strategies for cancer of unknown primary
inferred← citeshttps://doi.org/10.1007/s12672-024-01677-8openalex-snapshot
Nanomedicine mediated thyroid cancer diagnosis and treatment: an approach from generalized to personalized medicine
inferred← citeshttps://doi.org/10.1007/s13193-022-01612-9openalex-snapshot
Histopathological Evaluation and Molecular Diagnostic Tests for Peritoneal Metastases with Unknown Primary Site—a Review
inferred← citeshttps://doi.org/10.1007/s15004-020-8068-6openalex-snapshot
Das CUP-Syndrom - Stand 2020
inferred← citeshttps://doi.org/10.1016/j.annonc.2021.11.009openalex-snapshot
Open-label phase II study of the efficacy of nivolumab for cancer of unknown primary
inferred← citeshttps://doi.org/10.1016/j.clbc.2018.09.001openalex-snapshot
Potential Novel Therapy Targets in Neuroendocrine Carcinomas of the Breast
inferred← citeshttps://doi.org/10.1016/j.clbc.2020.02.008openalex-snapshot
Molecular Profiling of the Metaplastic Spindle Cell Carcinoma of the Breast Reveals Potentially Targetable Biomarkers
inferred← citeshttps://doi.org/10.1016/j.clon.2025.103944openalex-snapshot
The Use of Molecular Tools for Identifying and Guiding Treatment of Cancers of Unknown Primary: A Systematic Review
inferred← citeshttps://doi.org/10.1016/j.critrevonc.2020.102882openalex-snapshot
New rising entities in cancer of unknown primary: Is there a real therapeutic benefit?
inferred← citeshttps://doi.org/10.1016/j.critrevonc.2022.103700openalex-snapshot
The efficacy of immune checkpoint inhibitors in rare tumors: A systematic review of published clinical trials
inferred← citeshttps://doi.org/10.1016/j.ctrv.2018.04.011openalex-snapshot
The current evidence for a biomarker-based approach in cancer of unknown primary
inferred← citeshttps://doi.org/10.1016/j.ctrv.2021.102204openalex-snapshot
Redefining cancer of unknown primary: Is precision medicine really shifting the paradigm?
inferred← citeshttps://doi.org/10.1016/j.eclinm.2024.102991openalex-snapshot
Durvalumab and tremelimumab in patients with advanced rare cancer: a multi-centre, non-blinded, open-label phase II basket trial
inferred← citeshttps://doi.org/10.1016/j.ejca.2023.113377openalex-snapshot
Immune checkpoint inhibitors in patients with cancers of unknown primary
inferred← citeshttps://doi.org/10.1016/j.ejca.2024.114268openalex-snapshot
PD-L1 expression associates with favorable survival of patients with cancer of unknown primary (CUP) not treated with checkpoint inhibitors
inferred← citeshttps://doi.org/10.1016/j.ejca.2026.116696openalex-snapshot
Liver and peritoneal metastases of unknown primary site: French Intergroup Clinical Practice guidelines for diagnosis, treatment, and follow-up (TNCD, SNFGE, FFCD, UNICANCER, GERCOR, SFCD, SFED, SFP, SFR, ACHBT, SFRO, SNFCP, AFEF, RENAPE, NET-CAPI)
inferred← citeshttps://doi.org/10.1016/j.ejca.2026.116709openalex-snapshot
A non-randomized phase 2 trial of pembrolizumab in untreated patients with carcinoma of unknown primary site
inferred← citeshttps://doi.org/10.1016/j.esmoop.2024.103662openalex-snapshot
Unfavorable carcinoma of unknown primary with a gastrointestinal profile: a retrospective study
inferred← citeshttps://doi.org/10.1016/j.esmoop.2025.105312openalex-snapshot
Squamous cell carcinoma of unknown primary (SCCUP): a genomic landscape study
inferred← citeshttps://doi.org/10.1016/j.isci.2026.116351openalex-snapshot
Integrating artificial intelligence into cancers of unknown primary diagnosis and treatment
inferred← citeshttps://doi.org/10.1016/j.trecan.2020.11.002openalex-snapshot
Cancer of Unknown Primary in the Molecular Era
inferred← citeshttps://doi.org/10.1016/j.ymthe.2024.07.011openalex-snapshot
Synergic activity of FGFR2 and MEK inhibitors in the treatment of FGFR2-amplified cancers of unknown primary
inferred← citeshttps://doi.org/10.1038/s41379-018-0118-3openalex-snapshot
Molecular characterization of cancers with NTRK gene fusions
inferred← citeshttps://doi.org/10.1038/s41379-021-00923-6openalex-snapshot
Eosinophilic vacuolated tumor (EVT) of kidney demonstrates sporadic TSC/MTOR mutations: next-generation sequencing multi-institutional study of 19 cases
inferred← citeshttps://doi.org/10.1038/s41379-021-00967-8openalex-snapshot
Correction to: Eosinophilic vacuolated tumor (EVT) of kidney demonstrates sporadic TSC/MTOR mutations: next-generation sequencing multi-institutional study of 19 cases
inferred← citeshttps://doi.org/10.1038/s41416-018-0332-2openalex-snapshot
Molecular characterisation and liquid biomarkers in Carcinoma of Unknown Primary (CUP): taking the ‘U’ out of ‘CUP’
inferred← citeshttps://doi.org/10.1038/s41416-019-0723-zopenalex-snapshot
Exploring the biological hallmarks of cancer of unknown primary: where do we stand today?
inferred← citeshttps://doi.org/10.1038/s41416-022-01824-4openalex-snapshot
Intrahepatic cholangiocarcinoma hidden within cancer of unknown primary
inferred← citeshttps://doi.org/10.1038/s41416-026-03519-6openalex-snapshot
A prospective national precision medicine trial evaluating the feasibility of blood-based molecular profiling in patients with Cancer of Unknown Primary (CUP-COMP)
inferred← citeshttps://doi.org/10.1038/s41467-023-42400-5openalex-snapshot
Nivolumab and ipilimumab in recurrent or refractory cancer of unknown primary: a phase II trial
inferred← citeshttps://doi.org/10.1038/s41467-026-72745-6openalex-snapshot
Anti-PD-1 plus nab-paclitaxel and bevacizumab for second-line treatment of cancer of unknown primary (Fudan CUP-002): a phase II trial
inferred← citeshttps://doi.org/10.1038/s41571-020-0359-1openalex-snapshot
Progress in refining the clinical management of cancer of unknown primary in the molecular era
inferred← citeshttps://doi.org/10.1038/s41571-024-00932-9openalex-snapshot
Tumour mutational burden: clinical utility, challenges and emerging improvements
inferred← citeshttps://doi.org/10.1038/s41571-025-01060-8openalex-snapshot
Rethinking cancer of unknown primary: from diagnostic challenge to targeted treatment
inferred← citeshttps://doi.org/10.1053/j.seminoncol.2019.08.003openalex-snapshot
An updated review of microsatellite instability in the era of next-generation sequencing and precision medicine
inferred← citeshttps://doi.org/10.1080/14737140.2020.1807948openalex-snapshot
The diagnostic challenges of patients with carcinoma of unknown primary
inferred← citeshttps://doi.org/10.1093/annonc/mdz116openalex-snapshot
ESMO recommendations on microsatellite instability testing for immunotherapy in cancer, and its relationship with PD-1/PD-L1 expression and tumour mutational burden: a systematic review-based approach
inferred← citeshttps://doi.org/10.1093/bib/bbac161openalex-snapshot
Refinement of computational identification of somatic copy number alterations using DNA methylation microarrays illustrated in cancers of unknown primary
inferred← citeshttps://doi.org/10.1093/jjco/hyab173openalex-snapshot
A novel Lynch syndrome pedigree bearing germ-line MSH2 missense mutation c.1808A>T (Asp603Val)
inferred← citeshttps://doi.org/10.1097/cco.0000000000001066openalex-snapshot
The evolution of molecular management of carcinoma of unknown primary
inferred← citeshttps://doi.org/10.1097/md.0000000000036796openalex-snapshot
Pelvic metastatic squamous cell carcinoma of unknown primary site: A case report and brief literature review
inferred← citeshttps://doi.org/10.1097/md.0000000000037057openalex-snapshot
Pelvic squamous cell carcinoma of unknown primary origin with hydronephrosis and ureteral stricture: A case report
inferred← citeshttps://doi.org/10.1097/pai.0000000000000808openalex-snapshot
Biomarkers of Targeted Therapy and Immuno-Oncology in Cancers Metastatic to the Breast
inferred← citeshttps://doi.org/10.1097/pai.0000000000000884openalex-snapshot
Molecular Profiling Reveals Limited Targetable Biomarkers in Neuroendocrine Carcinoma of the Cervix
inferred← citeshttps://doi.org/10.1097/pas.0000000000002162openalex-snapshot
Fetal Type Morphologies Suggest the Presence of DICER1 Hotspot Mutations in Non–small Cell Lung Cancer
inferred← citeshttps://doi.org/10.1111/cup.14008openalex-snapshot
Poroid adnexal skin tumors with YAP1 fusions exhibit similar histopathologic features: A series of six YAP1 ‐rearranged adnexal skin tumors
inferred← citeshttps://doi.org/10.1111/eci.13583openalex-snapshot
Genomic correlates of response and resistance to immune checkpoint inhibitors in carcinomas of unknown primary
inferred← citeshttps://doi.org/10.1136/bmj.m4050openalex-snapshot
Cancer of unknown primary
inferred← citeshttps://doi.org/10.1136/jitc-2019-000347openalex-snapshot
Phase 2 study of pembrolizumab in patients with advanced rare cancers
inferred← citeshttps://doi.org/10.1136/jitc-2022-004822openalex-snapshot
Efficacy of pembrolizumab in patients with advanced cancer of unknown primary (CUP): a phase 2 non-randomized clinical trial
inferred← citeshttps://doi.org/10.1136/jitc-2022-005809openalex-snapshot
Immune and genomic biomarkers of immunotherapy response in cancer of unknown primary
inferred← citeshttps://doi.org/10.1155/crgm/3296346openalex-snapshot
A Case of Adenocarcinoma of Unknown Primary Site in a Lynch Syndrome Patient Responds to Ipilimumab/Nivolumab
inferred← citeshttps://doi.org/10.1159/000539650openalex-snapshot
Cancer of Unknown Primary: When Imaging, Pathology, and Molecular Biology Do Not Match
inferred← citeshttps://doi.org/10.1186/s12885-019-6372-zopenalex-snapshot
Fatal myositis and spontaneous haematoma induced by combined immune checkpoint inhibitor treatment in a patient with pancreatic adenocarcinoma
inferred← citeshttps://doi.org/10.1186/s12885-023-10794-6openalex-snapshot
Risk factors for cancer of unknown primary: a literature review
inferred← citeshttps://doi.org/10.1186/s12885-024-12437-wopenalex-snapshot
Programmed death-ligand 1 expression in carcinoma of unknown primary
inferred← citeshttps://doi.org/10.1186/s12885-025-14778-6openalex-snapshot
Clinical efficacy of immune checkpoint inhibitors for cancer of unknown primary: a multi-center retrospective study
inferred← citeshttps://doi.org/10.1186/s40425-019-0720-zopenalex-snapshot
Clinical and immune profiling for cancer of unknown primary site
inferred← citeshttps://doi.org/10.1200/jco.19.00449openalex-snapshot
Challenge of the Unknown: How Can We Improve Clinical Outcomes in Cancer of Unknown Primary?
inferred← citeshttps://doi.org/10.1200/jco.19.00767openalex-snapshot
Reply to A.-M. Conway et al
inferred← citeshttps://doi.org/10.1371/journal.pone.0259240openalex-snapshot
Hotspots and trends in liver kinase B1 research: A bibliometric analysis
inferred← citeshttps://doi.org/10.1634/theoncologist.2019-0798openalex-snapshot
Molecular Profiles of Brain and Pulmonary Metastatic Disease in Cancer of Unknown Primary
inferred← citeshttps://doi.org/10.1634/theoncologist.2020-0234openalex-snapshot
Defining a Distinct Immunotherapy Eligible Subset of Patients with Cancer of Unknown Primary Using Gene Expression Profiling with the 92-Gene Assay
inferred← citeshttps://doi.org/10.18632/oncotarget.26233openalex-snapshot
ROS1-rearranged putative lung adenocarcinoma presenting as carcinoma of unknown primary site: a case report
inferred← citeshttps://doi.org/10.20344/amp.17680openalex-snapshot
Portuguese Consensus Recommendations for Next-Generation Sequencing of Lung Cancer, Rare Tumors, and Cancers of Unknown Primary Origin in Clinical Practice
inferred← citeshttps://doi.org/10.21294/1814-4861-2022-21-6-38-46openalex-snapshot
Genetic features of cancer of unknown primary
inferred← citeshttps://doi.org/10.2147/cmar.s319179openalex-snapshot
A Systematic Review of Cancer of Unknown Primary in the Head and Neck Region
inferred← citeshttps://doi.org/10.2217/fon-2019-0108openalex-snapshot
Advances in the Management of Brain Metastases from Cancer of Unknown Primary
inferred← citeshttps://doi.org/10.29011/2574-7754.100713openalex-snapshot
Immune-Mediated Complete Response in a Patient with Carcinoma of Unknown Primary: A Case Report
inferred← citeshttps://doi.org/10.33590/emjoncol/10314365openalex-snapshot
Genomic Profiling Clinical Trials in Cancer of Unknown Primary
inferred← citeshttps://doi.org/10.3389/fgene.2023.1085549openalex-snapshot
The diagnosis and treatment for a patient with cancer of unknown primary: A case report
inferred← citeshttps://doi.org/10.3389/fimmu.2021.749204openalex-snapshot
Case Report: Immune and Genomic Characteristics Associated With Hyperprogression in a Patient With Metastatic Deficient Mismatch Repair Gastrointestinal Cancer Treated With Anti-PD-1 Antibody
inferred← citeshttps://doi.org/10.3389/fimmu.2022.1088683openalex-snapshot
Long-term benefit of immunotherapy in a patient with squamous lung cancer exhibiting mismatch repair deficient/high microsatellite instability/high tumor mutational burden: A case report and literature review
inferred← citeshttps://doi.org/10.3389/fimmu.2023.1181444openalex-snapshot
Immunochemotherapy achieved a complete response for metastatic adenocarcinoma of unknown primary based on gene expression profiling: a case report and review of the literature
inferred← citeshttps://doi.org/10.3389/fonc.2019.00402openalex-snapshot
Does Cancer of Unknown Primary (CUP) Truly Exist as a Distinct Cancer Entity?
inferred← citeshttps://doi.org/10.3389/fonc.2019.01546openalex-snapshot
“Metastatic Cancer of Unknown Primary” or “Primary Metastatic Cancer”?
inferred← citeshttps://doi.org/10.3389/fonc.2020.00533openalex-snapshot
The Quest for Improving Treatment of Cancer of Unknown Primary (CUP) Through Molecularly-Driven Treatments: A Systematic Review
inferred← citeshttps://doi.org/10.3389/fonc.2023.1242460openalex-snapshot
2-Year survival benefit from immunotherapy for squamous cell cancer with cancer of unknown primary in mediastinum: a case report
inferred← citeshttps://doi.org/10.3389/fonc.2026.1741467openalex-snapshot
Targeted and immunotherapy based on tissue of origin in carcinoma of unknown primary: a two-case report and literature review
inferred← citeshttps://doi.org/10.3390/cancers13030451openalex-snapshot
Cancer of Unknown Primary: Challenges and Progress in Clinical Management
inferred← citeshttps://doi.org/10.3390/cancers15205084openalex-snapshot
An Updated Review of the Biomarkers of Response to Immune Checkpoint Inhibitors in Merkel Cell Carcinoma: Merkel Cell Carcinoma and Immunotherapy
inferred← citeshttps://doi.org/10.3390/ijms19072087openalex-snapshot
Towards Molecular Profiling in Multiple Myeloma: A Literature Review and Early Indications of Its Efficacy for Informing Treatment Strategies
inferred← citeshttps://doi.org/10.3390/ijms23095213openalex-snapshot
Challenges in Metabolomics-Based Tests, Biomarkers Revealed by Metabolomic Analysis, and the Promise of the Application of Metabolomics in Precision Medicine
inferred← citeshttps://doi.org/10.3390/ijms24065588openalex-snapshot
From Biology to Diagnosis and Treatment: The Ariadne’s Thread in Cancer of Unknown Primary
inferred← citeshttps://doi.org/10.3390/metabo9060108openalex-snapshot
Translational Metabolomics: Current Challenges and Future Opportunities
inferred← citeshttps://doi.org/10.3410/f.737591174.793587645openalex-snapshot
Faculty Opinions recommendation of Phase 2 study of pembrolizumab in patients with advanced rare cancers.
inferred← citeshttps://doi.org/10.4103/jrms.jrms_520_24openalex-snapshot
Epidemiologic, histopathological, and prognostic analysis of cancer of unknown primary in an Iranian population
inferred← citeshttps://doi.org/10.5644/ama2006-124.392openalex-snapshot
Tumor-Type Agnostic, Targeted Therapies: BRAF Inhibitors Join the Group
inferred← citeshttps://doi.org/10.6084/m9.figshare.22625633openalex-snapshot
Additional file 1 of Risk factors for cancer of unknown primary: a literature review
inferred← citeshttps://doi.org/10.6084/m9.figshare.22625636openalex-snapshot
Additional file 2 of Risk factors for cancer of unknown primary: a literature review
inferred← citeshttps://doi.org/10.6084/m9.figshare.25989137openalex-snapshot
Additional file 1 of Programmed death-ligand 1 expression in carcinoma of unknown primary
Editorial review for independent work. ICSAC — the Institute for Complexity Science and Advanced Computing — runs a structured editorial panel for researchers publishing outside journals, and publishes on CiteStamp rails. Submission is free and goes through ORCID: icsacinstitute.org/submit.